<p>Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study</p>

Abstract

We aimed to compare clinical characteristics between Asian and Western chronic obstructive pulmonary disease (COPD) patients. This was a sub-analysis of an international, multicenter, prospective cohort study. Asian patients were enrolled in Singapore and South Korea. Western patients were enrolled in Spain, Poland, Ireland, the United Kingdom, and Malta. A total of 349 patients were analyzed. Among them, 110 (32%) patients were Asian and 239 (68%) Western. Male sex was more predominant in Asian than in Western (95% versus 63%, respectively; P <0.01). Body mass index was significantly lower in Asian (23.5 versus 27.1; P <0.01). The proportion of patients with a history of exacerbation was lower in Asian (12% versus 64%; P <0.01). Although patients were enrolled by same inclusion criteria, there were several differences between Asian and Western COPD patients. Our study has shown unbiased real-world differences between Asian and Western COPD patients. Since prospective follow-up study is currently ongoing, the result of this study can be fundamental base of future analysis.

<p>Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study</p>

“…17,24 The underlying cause of these effects remains unclear, but may be related to the Hawthorne effect, a process by which study participants experience improved outcomes regardless of their treatment allocation. 27 In addition, 95% of the patients in this study were male, which is consistent with a previous study in Asian patients with COPD 18 but may limit generalizability of the findings to the broader patient population. Despite this, the study provides valuable data on the efficacy and safety of UMEC 62.5 mcg compared with placebo in a population of Asian patients with COPD, providing useful and relevant information for prescribing physicians in Asia.…”

“…A comparison of baseline characteristics in an international COPD trial demonstrated baseline differences between Western and Asian patients, with the Asian study population containing a higher proportion of men, had a lower body mass index, and a higher incidence of exacerbations. 18 Study population differences and racial differences in socioeconomic status and clinical practice 4,19,20 could influence the relative efficacy and safety of therapy in patients with COPD, and it is therefore important to assess therapies in different ethnic populations. The aim of this study was to evaluate the efficacy and safety of UMEC compared with placebo in Asian patients with COPD.…”

Predictive value of control of COPD for risk of exacerbations: An international, prospective study

“…It is likely that a step up in treatment in non-controlled patients may change their status to controlled and reduce the future risks, but this has to be demonstrated in future interventional studies. Among the strengths, it includes a large population of patients with different degrees of severity recruited in several countries from Europe and Asia 10 and with a wide range of comorbidities, likely reflecting the real population of patients with COPD attended in specialized centres. 23 In conclusion, the current study has demonstrated that the proposed definition of control in COPD is useful in clinical practice.…”

“…This international, multicentre, prospective, study of a cohort of patients with COPD aimed to validate the concept of clinical control in COPD. The design of the study and the evaluation of the control status at baseline have been published previously . Briefly, this was a 21‐month prospective observational study, comprising five evaluation points: one screening evaluation (V‐1), one baseline visit after 3 months (V0) and three follow‐up visits at 6 months intervals (V1–V3).…”

Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study

“…This was a prospective international, multicenter study aimed at validating developing the concept of control in COPD. The design of the study has been described in detail in previous publications (8)(9)(10). Eligible patients were recruited to the study and underwent a screening visit (V-1) involving full clinical assessment, including socioeconomic variables, evaluation of current smoking status, current treatment, respiratory symptoms, presence of comorbidities, lung function measured by spirometry and questionnaires.…”